Pre-market 19 Mar 2026: ZBH.SW Zimmer Biomet (SIX) CHF67.50 -4.26%: analyst grade

ZBH.SW stock opened pre-market on 19 Mar 2026 at CHF67.50, down CHF3.00 or -4.26% versus the previous close on the SIX Swiss exchange. The fall places Zimmer Biomet Holdings, Inc. near its 52-week low of CHF67.50, after a year high of CHF119.00. Volume is light at 110.00 shares versus an average of 3.00, amplifying short-term volatility. We summarise the drivers, valuation, technicals and Meyka AI grade and forecast to help frame next moves for traders and investors.

ZBH.SW stock: price action and session context

Zimmer Biomet (ZBH.SW) is the top pre-market loser on SIX at CHF67.50, down 4.26% on the morning. The session low and high are both CHF67.50, showing an early directional move. Light traded volume (110.00) versus average (3.00) suggests the move may be driven by block orders or cross-listed arbitrage rather than broad retail selling.

Valuation snapshot and key metrics

At CHF67.50, ZBH.SW trades at PE 24.37 with EPS CHF2.77 and market capitalisation of CHF13,206,510,270.00. Price to book is 1.32 and EV/EBITDA is 11.51, while free cash flow yield stands at 9.48%. The stock sits below its 50-day average CHF78.58 and 200-day average CHF87.90, signaling near-term weakness against longer-term averages.

Meyka AI rates ZBH.SW with a score out of 100 and valuation view

Meyka AI rates ZBH.SW with a score out of 100: 77.48 / Grade B+ — Suggestion: BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus. The rating highlights strong cash generation (operating cash flow per share CHF8.61) against leverage (net debt to EBITDA 3.38). Grades are model outputs, not guarantees, and do not constitute financial advice.

Technicals, liquidity and sector comparison

Technicals show an overbought RSI at 75.66 but a strong ADX of 84.17, indicating trend strength mixed with short-term exhaustion. Inventory-heavy metrics (days of inventory on hand 311.18) and net debt pressures contrast with sector averages; the Healthcare sector average PE is 28.90, so ZBH.SW’s PE of 24.37 reads as modestly cheaper versus peers on earnings multiple.

Earnings calendar, catalysts and forecasts

Zimmer Biomet reports next on 2026-05-04. Key upcoming catalysts include quarterly results, U.S. procedure trends and product approvals. Meyka AI’s forecast model projects a monthly target CHF59.16 and quarterly CHF87.16, reflecting scenario-driven variance. Forecasts hinge on procedure volumes and margin recovery; model outputs are projections and not guarantees.

Risks, near-term outlook and trading strategy

Primary risks: slowing procedure volumes, supply-chain inventory drag and higher interest costs given net debt to EBITDA at 3.38. For pre-market traders, the low average traded volume (3.00) raises execution risk. Analysts recommend watching the CHF67.50 support and the CHF78.58 50-day average for potential mean-reversion. See our live quote page for updates: ZBH.SW on Meyka AI.

Final Thoughts

ZBH.SW stock opened pre-market at CHF67.50 on 19 Mar 2026, marking a -4.26% move into an already weak multi-month trend versus the 50- and 200-day averages. Meyka AI’s forecast model projects a yearly target of CHF58.07, implying an estimated downside of -13.97% from the current price. By contrast the quarterly model at CHF87.16 implies potential upside of +29.12%, which underlines model sensitivity to near-term procedure volumes and margin recovery. Valuation metrics — PE 24.37, price to book 1.32, and free cash flow yield 9.48% — point to a stock that looks reasonably valued versus sector peers but faces execution and volume risks. Meyka AI’s grade (B+, 77.48/100) flags the company’s cash generation but notes leverage and operational noise. Traders should treat today’s pre-market drop cautiously given thin Swiss trading volumes; longer-term investors should watch May earnings and procedure trends before adjusting position sizes. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.